Get to Know Dr. Thomas E. Stinchcombe
Dr. Thomas E. Stinchcombe is a medical oncologist at the Duke Cancer Center in Durham, North Carolina, specializing in the treatment of lung cancer and pleural mesothelioma along with other thoracic diseases.
Much of his research involves immunotherapy drugs and molecular therapies. He has received multiple grants to study novel agents such as nivolumab, bevacizumab and pembrolizumab, which are being used today for lung cancer and mesothelioma.
As part of the multidisciplinary approach to treatment at Duke, Stinchcombe works closely with thoracic surgeons and radiation oncologists who also specialize in treating lung and mesothelioma cancers.
“There are some promising new therapies for these diseases, and we are fortunate to have those available for patients here at Duke,” he said. “That’s one of the things we can offer as an academic medical center.”
Specialties of Dr. Thomas E. Stinchcombe
- Pleural mesothelioma
- Lung cancer
- Molecular therapy
- Thoracic oncology
- Clinical trials
Dr. Thomas E. Stinchcombe’s Experience and Education
- Duke University Cancer Center
- Professor of medicine, Duke University
- University of North Carolina School of Medicine (Fellowships)
- University of Michigan (Residency)
- University of Virginia School of Medicine (M.D.)
Awards and Certifications
- American Board of Internal Medicine
- North Carolina state medical license
- Healthgrades Honor Roll
Publications of Dr. Thomas E. Stinchcombe
- Stinchcombe, T.E. (2020, August). IMpower 131: The Exception to the Rule. Journal of Thoracic Oncology.
- Stinchcombe, T.E. (2020, July 26). Current management of RET rearranged non-small cell lung cancer. Therapeutic Advances in Medical Oncology
- Ludmir, E.B. et al. (2020, February 1). Sex-based Disparities Among Cancer Clinical Trial Participants. Journal of the National Cancer Institute.
- Socinski, M.A. et al. (2016, September). Clinicopathologic Features of Advanced Squamous NSCLC. Journal of Thoracic Oncology.